4.4 Article

Improved performance and safety from Argus II retinal prosthesis post-approval study in France

Journal

ACTA OPHTHALMOLOGICA
Volume 99, Issue 7, Pages E1212-E1221

Publisher

WILEY
DOI: 10.1111/aos.14728

Keywords

retinitis pigmentosa; retinal prosthesis; retinal implant; Argus II; daily activities; quality of life

Categories

Ask authors/readers for more resources

The study evaluated the long-term outcomes of the Argus II Retinal Prosthesis on patients with end-stage retinitis pigmentosa, focusing on its functional visual benefit in daily activities. Results showed positive impacts on functional vision and well-being, with improvement in daily tasks and standardized visual assessments for over 70% of subjects. The system was found to be safe and effective, with only two serious adverse events observed.
Purpose To evaluate the post-approval long-term outcomes of the Argus II Retinal Prosthesis, with a specific focus on its functional visual benefit in patients' daily activities. Methods Eighteen patients with bare light perception due to end-stage retinitis pigmentosa were included in a French prospective, multicentre, single-arm study and followed for 2 years. Visual benefit in patients' daily activities was monitored through the use of the Functional Low-vision Observer Rated Assessment (FLORA), and the final score at 2 years was the primary effectiveness outcome. Standardized visual assessments were also performed. Device- or procedure-related adverse events were recorded. Results Seventeen subjects completed the study. Positive impacts of the Argus II system on functional vision and well-being were demonstrated for over 70% of subjects on the FLORA. Among the daily activities/tasks tested, finding doorways was one of the most statistically significantly improved tasks (p < 0.001), along with estimating the size of an obstacle (p < 0.001), visually locating a place setting on a dining table (p < 0.001) and visually locating people in a non-crowded setting (p < 0.001). Visual function was improved on most standardized tests. Only two device- or procedure-related serious adverse events were observed (one vitreous haemorrhage and one endophthalmitis, both resolved with treatment). No explantation was required. Conclusion This first report of a completed post-approval study of Argus II with a two-year follow-up demonstrates the safety and effectiveness of the Argus II System in a real-world cohort of patients and further highlights its real functional benefit in implanted patients' daily activities.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available